The Effectiveness of Teclistamab in Patients With Relapsed/Refractory Light Chain Amyloidosis: A Multicenter Retrospective Study
British Journal of Hospital Medicine · 23.10.2026 · 87 (10)
DOI: 10.31083/bjhm62006 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Hospital Medicine, online erschienen am 23.10.2026. Verfasst von Cheng-Yang Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100000 Beijing…. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Antibodies, Bispecific. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences (CIFMS), National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Aims/Background: Teclistamab is a B-cell maturation antigen (BCMA)-directed bispecific monoclonal antibody recommended for relapsed/refractory multiple myeloma (RRMM) management. However, some small-scale studies support the application of teclistamab in relapsed/refractory light chain (RRAL) amyloidosis, primarily secondary to multiple myeloma (MM). Therefore, this study evaluated the efficacy and safety profile of teclistamab in daratumumab-pretreated RRAL amyloidosis patients.
Methods
After dose escalation, 19 patients across five centers, enrolled from October 2024 to July 2025, received teclistamab at a fixed dose (60 mg, n = 13) or weight-based administration (1.5 mg/kg, n = 6). Patients were followed up, and treatment response was monitored by evaluating hematologic, hepatic, cardiac, and renal involvement, as well as by examining the associated complications. The dosing frequency was reduced as hematologic efficacy improved, adjusted by the treating physician.
Results
At a median 4.0-month follow-up (interquartile range [IQR], 3–8), teclistamab demonstrated profound hematologic responses and organ improvement. 94.7% of patients achieved a stringent difference between involved and uninvolved free light chain (dFLC) response at a median time of 18.5 days. The weight-based and fixed-dose groups had comparable time to stringent dFLC response (median 20.5 days [IQR, 18–26] vs 17.5 days [IQR, 11–27], p = 0.385). Furthermore, 68.4% of the patients showed a significant cardiac response. Adverse events observed following treatment included cytokine release syndrome (ten events, all ≤grade 2), immune effector cell-associated neurotoxicity syndrome (one event, grade 1), and associated infections (ten events, 4 ≥grade 3).
Conclusion
These results indicate teclistamab as a practical option for daratumumab-exposed RRAL amyloidosis, supporting that fixed-dose strategy and timely reduction of dosing frequency guided by therapeutic efficacy appear to be feasible real-world approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100000 Beijing, China.
- Department of Hematology, First Affiliated Hospital, Jinan University, 510000 Guangzhou, Guangdong, China.
- Department of Hematology, Guangdong Provincial People's Hospital, Southern Medical University, 510000 Guangzhou, Guangdong, China.
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430000 Wuhan, Hubei, China.
- Department of Hematology, Bone Marrow Transplantation Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, 310000 Hangzhou, Zhejiang, China.
- Center for Rare Diseases, State Key Laboratory of Complex, Severe, and Rare Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 100000 Beijing, China.
Förderung
- National Natural Science Foundation of China
- CAMS Innovation Fund for Medical Sciences (CIFMS)
- National High Level Hospital Clinical Research Funding
- Peking Union Medical College Hospital Talent Cultivation Program
Zitieren
APA
Xu, C. Y., Zhong, L. Y., Lai, P. L., Sun, C. Y., He, D. H., Guan, A., Xu, Y., Shen, K., & Li, J. (2026). The Effectiveness of Teclistamab in Patients With Relapsed/Refractory Light Chain Amyloidosis: A Multicenter Retrospective Study. British Journal of Hospital Medicine, 87(10). https://doi.org/10.31083/bjhm62006
Vancouver
Xu CY, Zhong LY, Lai PL, Sun CY, He DH, Guan A, et al. The Effectiveness of Teclistamab in Patients With Relapsed/Refractory Light Chain Amyloidosis: A Multicenter Retrospective Study. British Journal of Hospital Medicine. 2026;87(10). doi:10.31083/bjhm62006
BibTeX
@article{Xu2026,
author = {Xu, Cheng-Yang and Zhong, Li-Ye and Lai, Pei-Long and Sun, Chun-Yan and He, Dong-Hua and Guan, Ai and Xu, Yi and Shen, Kaini and Li, Jian},
title = {The Effectiveness of Teclistamab in Patients With Relapsed/Refractory Light Chain Amyloidosis: A Multicenter Retrospective Study},
journal = {British Journal of Hospital Medicine},
year = {2026},
volume = {87},
number = {10},
doi = {10.31083/bjhm62006}
}
EUVIMED